Star Therapeutics Raises $125M as Bleeding Disorder Therapy Enters Phase III

Star Therapeutics announced a $125 million Series D financing round in late September 2025 led by multiple biotech investors135.

The funds will be used to advance Star’s pipeline, most notably VGA039, its lead program targeting rare bleeding disorders with a novel antibody therapy5.

VGA039 is entering a Phase III clinical trial, signaling a major milestone in its development aimed at treating patients with severe bleeding conditions5.

Star Therapeutics is focused on developing treatments for rare hematologic diseases, with this financing supporting clinical research, manufacturing, and regulatory work35.

The Series D round was described as 'oversubscribed,' indicating significant investor interest and confidence in the company’s therapeutic approach5.

Sources:

1. https://www.thepharmaletter.com/biotechnology/star-therapeutics-announces-125-millions-series-d-financing

3. https://www.axios.com/pro/biotech-deals/2025/09/30/star-therapeutics-raises-125m

5. https://star-therapeutics.com/star-therapeutics-announces-oversubscribed-125-million-series-d-financing/